Prescription drug · BLA
Tecentriq Hybreza (Atezolizumab and hyaluronidase-tqjs) NDC 50242-933
Atezolizumab 1875 mg/15mL; Hyaluronidase (Human recombinant) 30000 U/15mL · Injection · Subcutaneous · Genentech, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50242-933-01 | 50242093301 | 1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-01) / 15 mL in 1 VIAL, SINGLE-DOSEMarketed from Sep 12, 2024 | |
| 50242-933-86 | 50242093386 | 1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-86) / 15 mL in 1 VIAL, SINGLE-DOSEMarketed from Sep 12, 2024 · Sample package |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tecentriq Hybreza
- Generic name (nonproprietary)
- atezolizumab and hyaluronidase-tqjs
- Active ingredients
- Atezolizumab — 1875 mg/15mLHyaluronidase (Human recombinant) — 30000 U/15mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Labeler
- Genentech, Inc.NDC labeler code 50242
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761347
- Marketing start
- Listing expires
- Other FDA classes
- Antibodies (Chemical structure)Monoclonal (Chemical structure)Humanized (Chemical structure)Glycoside Hydrolases (Chemical structure)Programmed Death Receptor-1-directed Antibody Interactions (Mechanism)
- Identifiers
- Product ID 50242-933_391adb08-e25a-4e3f-a14c-f52e03b73fe8SPL ID 391adb08-e25a-4e3f-a14c-f52e03b73fe8
- Pharmacologic class
- Endoglycosidase; Programmed Death Receptor-1 Blocking Antibody
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N450242093301followed by a unit qualifier and the quantityPackage 50242-0933-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
The FDA listing for this product does not reference a label (SPL) set.
About NDC 50242-933
- What is NDC 50242-933?
- 50242-933 is the product NDC for Tecentriq Hybreza, Atezolizumab 1875 mg/15mL; Hyaluronidase (Human recombinant) 30000 U/15mL injection, listed with the FDA by Genentech, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Tecentriq Hybreza (Atezolizumab and hyaluronidase-tqjs).
- What is the active ingredient?
- Atezolizumab, Hyaluronidase (Human recombinant).
- Who is the labeler?
- Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Tecentriq Hybreza?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.